Merck & Co., Inc.

MRK

$80.39

-8.34% (1 year change)

Avg closing price

Price range

Market Cap

$202 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

$10.8 Billion

Total revenue in the last quarter.

Net Income

$3 Billion

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$4.54

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

$2.44 (3.06%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

17.58x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

$3.25 Billion

Earnings before interest expenses and taxes in the last quarter.

Employees

71,000

The number of full time employees.

Revenue & Earnings

Balance Sheet

Merck & Co., Inc.

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the Company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

News

Flutamide (CAS 13311-84-7) Market to Witness an Outstanding Growth by 2026| Forward, Merck, Tasly Diyi Pharma

Flutamide (CAS 13311-84-7) Market to Witness an Outstanding Growth by 2026| Forward, Merck, Tasly Diyi Pharma

The global Flutamide (CAS 13311-84-7) market is broadly analyzed in this report that sheds light on critical aspects such as the vendor landscape, competitive strategies, market dynamics, and regio...

OpenPR OpenPR, 4 days ago
Berkshire Hathaway expert Dr John Longo explains why Warren Buffett's company bet big on pharma, dumped Costco and JPMorgan, and smashed its buyback record last quarter

Berkshire Hathaway expert Dr John Longo explains why Warren Buffett's company bet big on pharma, dumped Costco and JPMorgan, and smashed its buyback record last quarter

Summary List Placement Warren Buffett's Berkshire Hathaway surprised many followers by plowing more than $5 billion into pharmaceutical stocks, selling its Costco stake , and slashing bank holdings...

Business Insider Business Insider, 6 days ago
Digitalization of Production: Merck and Siemens Collaborate - News | Merck global (Merck) | CompanyNewsHQ

Digitalization of Production: Merck and Siemens Collaborate - News | Merck global (Merck) | CompanyNewsHQ

(Merck) 26 Nov 2020 | Darmstadt, Germany Collaboration is to advance modular production in industry In the future, it will be possible to meet customer and market

CompanyNewsHQ CompanyNewsHQ, 7 days ago